References
- Mole RH. Whole body irradiation – radiobiology or medicine? Br J Radiol. 1953;26:234–41.10.1259/0007-1285-26-305-234
- Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203(5):1259–71.10.1084/jem.20052494
- Rubner Y, Wunderlich R, Rühle PF, Kulzer L, Werthmöler N, Frey B, et al. How does ionizing irradiation contribute to the induction of anti-tumor immunity? Front Oncol. 2012;2:75. doi:10.3389/fonc.2012.00075.
- De Meerleer G, Khoo V, Escudier B, Joniau S, Bossi A, Ost P, et al. Radiotherapy for renal-cell carcinoma. Lancet Oncol. 2014;15:e170–7.10.1016/S1470-2045(13)70569-2
- De Wolf K, Vermaelen K, De Meerleer G, Lambrecht BN, Ost P. The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy. OncoImmunology. 2015;4(10):e1042198.10.1080/2162402X.2015.1042198
- Teh BS, Bloch C, Paulino AC, Shen S, Hinckley L, Baskin D, et al. Pathologic complete response in renal cell carcinoma brain metastases treated with stereotactic radiosurgery. Clin Genitourin Cancer. 2007;5(5):334–7.10.3816/CGC.2007.n.013
- Wersäll PJ, Blomgren H, Pisa P, Lax I, Kälkner KM, Svedman C, et al. Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma. Acta Oncol. 2006;45(4):493–7.10.1080/02841860600604611
- Seung SK, Curti BD, Crittenden M, Walker E, Coffey T, Siebert JC, et al. Phase 1 study of stereotactic body radiotherapy and interleukin-2-tumor and immunological responses. Sci Transl Med. 2012;4:137ra74.
- Albiges L, Oudard S, Negrier S, Caty A, Gravis G, Joly F, et al. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol. 2012 Feb 10;30(5):482–7.10.1200/JCO.2011.37.2516
- Buchler T, Bortlicek Z, Poprach A, Pavlik T, Veskrnova V, Honzirkova M, et al. Outcomes for patients with metastatic renal cell carcinoma achieving a complete response on targeted therapy: a registry-based analysis. Eur Urol. 2015;12:1240–3.
- Iacovelli R, Alesini D, Palazzo A, Trenta P, Santoni M, De Marchis L, et al. Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials. Cancer Treat Rev. 2014;40:271–5.10.1016/j.ctrv.2013.09.003
- Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061–8.10.1200/JCO.2009.23.9764
- Biasco E, Antonuzzo A, Cianci C, Derosa L, Marconcini R, Farnesi A, et al. Early and prolonged response to pazopanib in a patient with multiple metastases from renal cell carcinoma: a case report. Tumori. 2014;100:e83–6.
- Bumpus HC. The apparent disappearance of pulmonary metastasis in a case of hypernephroma following nephrectomy. J Urol. 1928;20:185–91.
- Lokich J. Spontaneous regression of metastatic renal cancer: case report and literature review. Am J Clin Oncol. 1997;20(4):416–8.10.1097/00000421-199708000-00020
- Nakajima T, Suzuki M, Ando S, Iida T, Araki A, Fujisawa T, et al. Spontaneous regression of bone metastasis from renal cell carcinoma; a case report. BMC Cancer. 2006;6:11. doi:10.1186/1471-2407-6-11.10.1186/1471-2407-6-11